temozolomide has been researched along with Opportunistic Infections in 11 studies
Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases." | 7.88 | Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 7.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine." | 7.72 | Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004) |
| "Treatment of malignant gliomas has changed substantially over the last few years." | 5.35 | Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009) |
| "Temozolomide chemotherapy has become part of the therapy used to treat glioblastoma multiforme and refractory anaplastic astrocytoma." | 4.86 | Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. ( Aguado, JM; García-Reyne, A; Juan, RS; Lalueza, A; Lizasoain, M; López-Medrano, F; Martínez, P; Meije, Y; Rodríguez, V, 2010) |
| "Temozolomide, a key drug in the treatment of malignant glioma, can cause profound lymphopenia and various opportunistic infectious diseases." | 3.88 | Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide. ( Furukawa, R; Homma, H; Horiuchi, H; Inoue, T; Usui, K, 2018) |
| "Temozolomide is utilized as a treatment for a variety of solid tumors and has been associated with the development of selective lymphopenia." | 3.74 | Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. ( Baden, LR; Kulke, MH; Michelini, A; Schwarzberg, AB; Sengupta, T; Stover, EH; Vincitore, M, 2007) |
| "Standard schedule temozolomide (TMZ; daily for 5 days every 4 weeks) is often used in melanoma patients, but phase III data show that it is no more effective than standard dacarbazine." | 3.72 | Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. ( Chapman, PB; Foster, T; Krown, SE; Livingston, PO; Quinn, C; Sepkowitz, KA; Sohn, S; Su, YB; Williams, L; Wolchok, JD, 2004) |
| "Treatment of malignant gliomas has changed substantially over the last few years." | 1.35 | Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. ( Benekli, M; Buyukberber, N; Buyukberber, S; Coskun, O; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R, 2009) |
| "We report the case of a patient with primary brain tumor who developed cytomegalovirus associated colonic pseudotumor as an opportunistic infection while receiving chemotherapy with Temozolomide and radiation." | 1.35 | Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide. ( De Jesus, A; Grossman, SA; Paun, O, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jbeli, AH | 1 |
| Yu, J | 1 |
| Furukawa, R | 1 |
| Homma, H | 1 |
| Inoue, T | 1 |
| Horiuchi, H | 1 |
| Usui, K | 1 |
| Gorospe Sarasúa, L | 1 |
| Ureña-Vacas, A | 1 |
| Muñoz Del Toro, JR | 1 |
| Yaman, E | 1 |
| Coskun, U | 1 |
| Ozturk, B | 1 |
| Buyukberber, S | 1 |
| Kaya, AO | 1 |
| Coskun, O | 1 |
| Buyukberber, N | 1 |
| Yildiz, R | 1 |
| Benekli, M | 1 |
| De Jesus, A | 1 |
| Grossman, SA | 1 |
| Paun, O | 1 |
| Gousias, K | 1 |
| Konstantinos, G | 1 |
| Kyritsis, A | 1 |
| Athanasios, K | 1 |
| Meije, Y | 1 |
| Lizasoain, M | 1 |
| García-Reyne, A | 1 |
| Martínez, P | 1 |
| Rodríguez, V | 1 |
| López-Medrano, F | 1 |
| Juan, RS | 1 |
| Lalueza, A | 1 |
| Aguado, JM | 1 |
| Gajewski, TF | 1 |
| Su, YB | 1 |
| Sohn, S | 1 |
| Krown, SE | 1 |
| Livingston, PO | 1 |
| Wolchok, JD | 1 |
| Quinn, C | 1 |
| Williams, L | 1 |
| Foster, T | 1 |
| Sepkowitz, KA | 1 |
| Chapman, PB | 1 |
| Schwarzberg, AB | 1 |
| Stover, EH | 1 |
| Sengupta, T | 1 |
| Michelini, A | 1 |
| Vincitore, M | 1 |
| Baden, LR | 1 |
| Kulke, MH | 1 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Opportunistic Infections
| Article | Year |
|---|---|
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Cytomegalovirus Infection | 2010 |
10 other studies available for temozolomide and Opportunistic Infections
| Article | Year |
|---|---|
Blastomycosis and Histoplasmosis in a Patient with Glioblastoma Receiving Temozolomide.
Topics: Antineoplastic Agents, Alkylating; Blastomycosis; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazi | 2016 |
Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Cystitis; Cytomegalovirus Infectio | 2018 |
Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2016 |
Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; DN | 2009 |
Cytomegalovirus associated colonic pseudotumor: a consequence of iatrogenic immunosuppression in a patient with primary brain tumor receiving radiation and temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cytomegalovirus Infections; Dacarbazine; F | 2009 |
Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Topics: Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Glioma; Humans; Opportun | 2010 |
Temozolomide for melanoma: new toxicities and new opportunities.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Humans; Lymphopenia; M | 2004 |
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; CD4-Positive T-Lymphocytes; Dacar | 2004 |
Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cytomegalovirus Infections; Dacarbazine; Female; Her | 2007 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |